Skip to content

Detection of G-quadruplex DNA Methylation in Cancer

Early Diagnosis Value of G-quadruplex DNA Methylation in Patients with Cancer

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06537063
Enrollment
0
Registered
2024-08-05
Start date
2024-04-30
Completion date
2024-12-30
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Cell-free DNA, DNA G-quadruplex, Methylation

Brief summary

This study aims to evaluate the early diagnosis value of G-quadruplex DNA methylation in patients with cancer.

Detailed description

Global DNA hypomethylation is a hallmark of most cancers that occurs early during oncogenesis. We would like to investigate whether cancer-specific transcription factor binding to DNA G-quadruplex drives DNA hypomethylation in cancer. In this observational study, we would like to clarify whether DNA hypomethylation around G-quadruplex loci in cell-free DNA could be detected in early-stage cancer patients from healthy donors with high sensitivity and specificity.

Interventions

OTHERG4 DNAm test

Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.

Sponsors

Zhongnan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
42 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers identified as asymptomatic during medical examination; * Age≥42 years old; * Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

* History of malignancy or having achieved complete remission following tumor surgery; * Certain autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, Crohn's disease, IgA nephropathy, myasthenia gravis, dermatomyositis, immune thrombocytopenic purpura, etc.); * Pregnancy; * Acute trauma (including surgical procedures), sudden onset organ failure (e.g., resulting from a car accident, fulminant hepatic failure, acute pancreatitis, severe pneumonia due to influenza virus), or diagnosis of sepsis; * Previous receipt of allogeneic blood transfusion, transplant surgery, or allogeneic cell therapy; * Volunteers who cannot provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
G-quadruplex DNAm score2024.04.30-2024.09.30Detection of DNAm around G-quadruplex loci in cell-free DNA from blood.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026